Cyxone AB (CYXO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
27
About the Report
About the Report
Summary
Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company develops T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. It also offers cyclotides, a new class of highly specific low toxicity drugs that can be used for several immune-related diseases and cancers. Cyxone also develops biological drugs with pharmacological effects for MS sufferers and RRMS patients. The company also conducts preclinical studies and clinical trials. It operates across Austria and Germany. Cyxone is headquartered in Malmo, Sweden.
Cyxone AB (CYXO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Cyxone AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cyxone AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cyxone AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cyxone AB, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Cyxone Acquires Rights of Rabeximod from Oxypharma 10
Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 11
Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 12
Partnerships 13
Cyxone Partners with Medical University of Vienna 13
Cyxone Enters into Agreement with University of Queensland 14
Cyxone Enters into Agreement with Sourcia 15
Cyxone Enters into Agreement with Bachem 16
Cyxone AB-Key Competitors 17
Cyxone AB-Key Employees 18
Cyxone AB-Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Financial Announcements 20
Aug 17, 2018: Cyxone's interim report for January-June 2018 20
Feb 16, 2018: Cyxone : Year-end Report 1 January to 31 December 2017 22
Oct 26, 2017: Cyxone: Interim report July 1 to September 30, 2017 23
Aug 30, 2017: Cyxone: Interim report 2017-01-01 to 2017-06-30 24
Clinical Trials 25
Nov 01, 2017: Existing Rabeximod can be used in Cyxone's planned Phase 2b study in patients with rheumatoid arthritis 25
Other Significant Developments 26
Jun 29, 2018: Cyxone appoints Mangold as market maker 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27
List of Figure
List of Figures
Cyxone AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cyxone AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
List of Table
List of Tables
Cyxone AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cyxone AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cyxone AB, Deals By Therapy Area, 2012 to YTD 2018 8
Cyxone AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Cyxone Acquires Rights of Rabeximod from Oxypharma 10
Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 11
Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 12
Cyxone Partners with Medical University of Vienna 13
Cyxone Enters into Agreement with University of Queensland 14
Cyxone Enters into Agreement with Sourcia 15
Cyxone Enters into Agreement with Bachem 16
Cyxone AB, Key Competitors 17
Cyxone AB, Key Employees 18
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.